MG
JBIO

Michael Gelband’s Jade Biosciences JBIO Stock Holding History

Michael Gelband’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,131
Closed -$199K – 1573
2026
Q1 		$199K Sell
14,131
-273,456
-95% -$3.96M ﹤0.01% 1380
2025
Q4 		$4.44M Buy
+287,587
New +$3.37M 0.03% 515
2024
Q4 		– Sell
-603
Closed -$44K – 1520
2024
Q3 		$44K Sell
603
-18
-3% -$1.16K ﹤0.01% 1543
2024
Q2 		$36K Buy
+621
New +$412K ﹤0.01% 1451

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's JBIO Position: Q2 2026 in Review

Michael Gelband sold out of Jade Biosciences (JBIO) in Q2 2026, closing a stake of 14,131 shares — an estimated $199K sold.

Michael Gelband first reported a position in JBIO in Q2 2024 and held it in 4 quarters. The position peaked at $4.44M in Q4 2025. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Michael Gelband reported no remaining Jade Biosciences position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 14,131 Jade Biosciences shares in Q2 2026, an estimated $199K.
  • Michael Gelband first reported a position in Jade Biosciences in Q2 2024 and held it in 4 quarters.
  • Michael Gelband's Jade Biosciences position peaked at $4.44M in Q4 2025.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.